Antegrin Therapeutics is a technology company.
Antegrin Therapeutics has raised $800K across 1 funding round.
Antegrin Therapeutics has raised $800K in total across 1 funding round.
Antegrin Therapeutics has raised $800K in total across 1 funding round.
Antegrin Therapeutics's investors include iSelect Fund.
Antegrin Therapeutics LLC is a biotechnology company founded in 2012 and based in St. Louis, Missouri, specializing in drug discovery and development for fibrotic diseases.[1][2][3] It focuses on novel therapies, with its lead program targeting idiopathic pulmonary fibrosis—a progressive, life-threatening lung condition lacking FDA-approved treatments—and maintains a portfolio of small-molecule candidates.[1][4] The company serves patients with fibrotic conditions, addressing unmet needs in areas like pulmonary fibrosis by advancing pharmaceutical products through development.[1][3]
While specific recent growth metrics are unavailable in current sources, Antegrin has generated approximately $5.8 million in revenue, indicating early-stage operations in a high-need therapeutic space.[5]
Antegrin Therapeutics was founded in 2012 by David Griggs, who also serves as CEO, in St. Louis, Missouri, at 4320 Forest Park Ave., Ste. 304.[1] The company emerged from expertise in biotechnology and pharmaceuticals, with Griggs bringing leadership to focus on fibrotic diseases, starting with its lead program for idiopathic pulmonary fibrosis.[1] Early efforts centered on building a pipeline of novel small-molecule therapies, marking a pivotal shift toward addressing gaps in treatments for these progressive conditions, though detailed traction milestones beyond formation are not specified in available records.[1][4]
Antegrin rides the wave of precision medicine and fibrosis therapeutics, a growing biotech trend driven by aging populations and rising incidence of conditions like pulmonary fibrosis amid limited approved treatments.[1][2] Timing aligns with advances in small-molecule drug design, enabling targeted therapies where market forces favor orphan drug incentives and partnerships for rare diseases.[3][4] By advancing candidates in this space, Antegrin contributes to the biotech ecosystem, potentially influencing fibrosis research pipelines and supporting St. Louis as a biotech hub.[1][5]
Antegrin is positioned for pipeline milestones, such as clinical trial advancements in its idiopathic pulmonary fibrosis program, amid biotech trends like AI-driven drug discovery and fibrosis-focused M&A.[1][4] Evolving regulatory support for rare diseases could accelerate progress, though success hinges on trial data and funding in a competitive landscape. Its niche influence may grow through partnerships, amplifying impact in fibrotic therapies and echoing its origins in targeted innovation.[2][3]
Antegrin Therapeutics has raised $800K across 1 funding round. Most recently, it raised $800K Seed in October 2015.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2015 | $800K Seed | iSelect Fund |